Icon, which provides outsourced development services to drug and medical device makers, said the FDA warning is based on inspections of client and some clinical sites involved in the research trails of an antibiotic drug treatment for complicated skin infections.
Icon added that the unnamed client receive a similar message from the FDA.
In morning trading, Icon stocks fell $1.15, or 5.1 percent, to $21.53.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
